Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Integration of radiotherapy and immunotherapy for treatment of oligometastases.

Pitroda SP, Chmura SJ, Weichselbaum RR.

Lancet Oncol. 2019 Aug;20(8):e434-e442. doi: 10.1016/S1470-2045(19)30157-3. Epub 2019 Jul 29. Review.

PMID:
31364595
2.

Beyond Palliation: The Rationale for Metastasis-Directed Therapy for Metastatic Non-Small Cell Lung Cancer.

Foster CC, Pitroda SP, Weichselbaum RR.

J Thorac Oncol. 2019 Sep;14(9):1510-1512. doi: 10.1016/j.jtho.2019.05.025. Epub 2019 Jul 2. No abstract available.

PMID:
31272814
3.

Integrated molecular and clinical staging defines the spectrum of metastatic cancer.

Pitroda SP, Weichselbaum RR.

Nat Rev Clin Oncol. 2019 Sep;16(9):581-588. doi: 10.1038/s41571-019-0220-6. Review.

PMID:
31092903
4.

Staging the Metastatic Spectrum Through Integration of Clinical and Molecular Features.

Foster CC, Pitroda SP, Weichselbaum RR.

J Clin Oncol. 2019 May 20;37(15):1270-1276. doi: 10.1200/JCO.18.02021. Epub 2019 Apr 2. No abstract available.

PMID:
30939093
5.

DNA Methylation Controls Metastasis-Suppressive 14q32-Encoded miRNAs.

Oshima G, Poli EC, Bolt MJ, Chlenski A, Forde M, Jutzy JMS, Biyani N, Posner MC, Pitroda SP, Weichselbaum RR, Khodarev NN.

Cancer Res. 2019 Feb 1;79(3):650-662. doi: 10.1158/0008-5472.CAN-18-0692. Epub 2018 Dec 11.

PMID:
30538122
6.

Oligometastatic prostate cancer: Reality or figment of imagination?

Foster CC, Weichselbaum RR, Pitroda SP.

Cancer. 2019 Feb 1;125(3):340-352. doi: 10.1002/cncr.31860. Epub 2018 Dec 6. Review.

7.

Author Correction: Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis.

Pitroda SP, Khodarev NN, Huang L, Uppal A, Wightman SC, Ganai S, Joseph N, Pitt J, Brown M, Forde M, Mangold K, Xue L, Weber C, Segal JP, Kadri S, Stack ME, Khan S, Paty P, Kaul K, Andrade J, White KP, Talamonti M, Posner MC, Hellman S, Weichselbaum RR.

Nat Commun. 2018 Nov 13;9(1):4827. doi: 10.1038/s41467-018-07303-w.

8.

Safety and Efficacy of Hypofractionated Radiotherapy With Capecitabine in Elderly Patients With Urothelial Carcinoma.

Leng J, Akthar AS, Szmulewitz RZ, O'Donnell PH, Sweis RF, Pitroda SP, Smith N, Steinberg GD, Liauw SL.

Clin Genitourin Cancer. 2019 Feb;17(1):e12-e18. doi: 10.1016/j.clgc.2018.10.003. Epub 2018 Oct 12.

PMID:
30392939
9.

Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis.

Pitroda SP, Khodarev NN, Huang L, Uppal A, Wightman SC, Ganai S, Joseph N, Pitt J, Brown M, Forde M, Mangold K, Xue L, Weber C, Segal JP, Kadri S, Stack ME, Khan S, Paty P, Kaul K, Andrade J, White KP, Talamonti M, Posner MC, Hellman S, Weichselbaum RR.

Nat Commun. 2018 May 4;9(1):1793. doi: 10.1038/s41467-018-04278-6. Erratum in: Nat Commun. 2018 Nov 13;9(1):4827.

10.

JAK2 Inhibitor SAR302503 Abrogates PD-L1 Expression and Targets Therapy-Resistant Non-small Cell Lung Cancers.

Pitroda SP, Stack ME, Liu GF, Song SS, Chen L, Liang H, Parekh AD, Huang X, Roach P, Posner MC, Weichselbaum RR, Khodarev NN.

Mol Cancer Ther. 2018 Apr;17(4):732-739. doi: 10.1158/1535-7163.MCT-17-0667. Epub 2018 Feb 21.

11.

Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.

Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, Al-Hallaq HA, Arina A, Khodarev NN, Janisch L, Chang P, Patel JD, Fleming GF, Moroney J, Sharma MR, White JR, Ratain MJ, Gajewski TF, Weichselbaum RR, Chmura SJ.

J Clin Oncol. 2018 Jun 1;36(16):1611-1618. doi: 10.1200/JCO.2017.76.2229. Epub 2018 Feb 13.

12.

Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer.

Pitroda SP, Bao R, Andrade J, Weichselbaum RR, Connell PP.

Clin Cancer Res. 2017 Aug 1;23(15):4493-4500. doi: 10.1158/1078-0432.CCR-16-2845. Epub 2017 Mar 24.

13.

Advanced Animal Model of Colorectal Metastasis in Liver: Imaging Techniques and Properties of Metastatic Clones.

Oshima G, Stack ME, Wightman SC, Bryan D, Poli E, Xue L, Skowron KB, Uppal A, Pitroda SP, Huang X, Posner MC, Hellman S, Weichselbaum RR, Khodarev NN.

J Vis Exp. 2016 Nov 30;(117). doi: 10.3791/54657.

14.

Basal Tumor Cell Isolation and Patient-Derived Xenograft Engraftment Identify High-Risk Clinical Bladder Cancers.

Skowron KB, Pitroda SP, Namm JP, Balogun O, Beckett MA, Zenner ML, Fayanju O, Huang X, Fernandez C, Zheng W, Qiao G, Chin R, Kron SJ, Khodarev NN, Posner MC, Steinberg GD, Weichselbaum RR.

Sci Rep. 2016 Oct 24;6:35854. doi: 10.1038/srep35854.

15.

Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT).

Wong AC, Watson SP, Pitroda SP, Son CH, Das LC, Stack ME, Uppal A, Oshima G, Khodarev NN, Salama JK, Weichselbaum RR, Chmura SJ.

Cancer. 2016 Jul 15;122(14):2242-50. doi: 10.1002/cncr.30058. Epub 2016 May 20.

16.

Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs.

Ranoa DR, Parekh AD, Pitroda SP, Huang X, Darga T, Wong AC, Huang L, Andrade J, Staley JP, Satoh T, Akira S, Weichselbaum RR, Khodarev NN.

Oncotarget. 2016 May 3;7(18):26496-515. doi: 10.18632/oncotarget.8420.

17.

Imaging of tumor clones with differential liver colonization.

Oshima G, Wightman SC, Uppal A, Stack ME, Pitroda SP, Oskvarek JJ, Huang X, Posner MC, Hellman S, Weichselbaum RR, Khodarev NN.

Sci Rep. 2015 Jun 22;5:10946. doi: 10.1038/srep10946.

18.

Oncogenic CXCL10 signalling drives metastasis development and poor clinical outcome.

Wightman SC, Uppal A, Pitroda SP, Ganai S, Burnette B, Stack M, Oshima G, Khan S, Huang X, Posner MC, Weichselbaum RR, Khodarev NN.

Br J Cancer. 2015 Jul 14;113(2):327-35. doi: 10.1038/bjc.2015.193. Epub 2015 Jun 4.

19.

microRNAs and oligometastasis.

Khodarev NN, Pitroda SP, Weichselbaum RR.

Aging (Albany NY). 2015 Mar;7(3):146-7. No abstract available.

20.

14q32-encoded microRNAs mediate an oligometastatic phenotype.

Uppal A, Wightman SC, Mallon S, Oshima G, Pitroda SP, Zhang Q, Huang X, Darga TE, Huang L, Andrade J, Liu H, Ferguson MK, Greene GL, Posner MC, Hellman S, Khodarev NN, Weichselbaum RR.

Oncotarget. 2015 Feb 28;6(6):3540-52.

21.

DNA repair pathway gene expression score correlates with repair proficiency and tumor sensitivity to chemotherapy.

Pitroda SP, Pashtan IM, Logan HL, Budke B, Darga TE, Weichselbaum RR, Connell PP.

Sci Transl Med. 2014 Mar 26;6(229):229ra42. doi: 10.1126/scitranslmed.3008291.

22.

RIG-I-like receptor LGP2 protects tumor cells from ionizing radiation.

Widau RC, Parekh AD, Ranck MC, Golden DW, Kumar KA, Sood RF, Pitroda SP, Liao Z, Huang X, Darga TE, Xu D, Huang L, Andrade J, Roizman B, Weichselbaum RR, Khodarev NN.

Proc Natl Acad Sci U S A. 2014 Jan 28;111(4):E484-91. doi: 10.1073/pnas.1323253111. Epub 2014 Jan 13.

23.

Tumor endothelial inflammation predicts clinical outcome in diverse human cancers.

Pitroda SP, Zhou T, Sweis RF, Filippo M, Labay E, Beckett MA, Mauceri HJ, Liang H, Darga TE, Perakis S, Khan SA, Sutton HG, Zhang W, Khodarev NN, Garcia JG, Weichselbaum RR.

PLoS One. 2012;7(10):e46104. doi: 10.1371/journal.pone.0046104. Epub 2012 Oct 4.

24.

Evaluation of the prostate bed for local recurrence after radical prostatectomy using endorectal magnetic resonance imaging.

Liauw SL, Pitroda SP, Eggener SE, Stadler WM, Pelizzari CA, Vannier MW, Oto A.

Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):378-84. doi: 10.1016/j.ijrobp.2012.05.015. Epub 2012 Jun 18.

PMID:
22717242
25.

MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients.

MacDermed DM, Khodarev NN, Pitroda SP, Edwards DC, Pelizzari CA, Huang L, Kufe DW, Weichselbaum RR.

BMC Med Genomics. 2010 May 6;3:16. doi: 10.1186/1755-8794-3-16.

26.

Ad.Egr-TNF and local ionizing radiation suppress metastases by interferon-beta-dependent activation of antigen-specific CD8+ T cells.

Meng Y, Mauceri HJ, Khodarev NN, Darga TE, Pitroda SP, Beckett MA, Kufe DW, Weichselbaum RR.

Mol Ther. 2010 May;18(5):912-20. doi: 10.1038/mt.2010.18. Epub 2010 Mar 2.

27.

STAT1-dependent expression of energy metabolic pathways links tumour growth and radioresistance to the Warburg effect.

Pitroda SP, Wakim BT, Sood RF, Beveridge MG, Beckett MA, MacDermed DM, Weichselbaum RR, Khodarev NN.

BMC Med. 2009 Nov 5;7:68. doi: 10.1186/1741-7015-7-68.

28.

STAT1 pathway mediates amplification of metastatic potential and resistance to therapy.

Khodarev NN, Roach P, Pitroda SP, Golden DW, Bhayani M, Shao MY, Darga TE, Beveridge MG, Sood RF, Sutton HG, Beckett MA, Mauceri HJ, Posner MC, Weichselbaum RR.

PLoS One. 2009 Jun 8;4(6):e5821. doi: 10.1371/journal.pone.0005821.

29.

Radioresistance of Stat1 over-expressing tumour cells is associated with suppressed apoptotic response to cytotoxic agents and increased IL6-IL8 signalling.

Efimova EV, Liang H, Pitroda SP, Labay E, Darga TE, Levina V, Lokshin A, Roizman B, Weichselbaum RR, Khodarev NN.

Int J Radiat Biol. 2009 May;85(5):421-31. doi: 10.1080/09553000902838566. Erratum in: Int J Radiat Biol. 2009 Jul;85(7):642.

30.

MUC1-induced transcriptional programs associated with tumorigenesis predict outcome in breast and lung cancer.

Khodarev NN, Pitroda SP, Beckett MA, MacDermed DM, Huang L, Kufe DW, Weichselbaum RR.

Cancer Res. 2009 Apr 1;69(7):2833-7. doi: 10.1158/0008-5472.CAN-08-4513. Epub 2009 Mar 24.

31.

MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment.

Pitroda SP, Khodarev NN, Beckett MA, Kufe DW, Weichselbaum RR.

Proc Natl Acad Sci U S A. 2009 Apr 7;106(14):5837-41. doi: 10.1073/pnas.0812029106. Epub 2009 Mar 16.

Supplemental Content

Loading ...
Support Center